301015 百洋医药
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,594,708-1.10%7,563,9037,509,6187,051,5675,879,323
减:营业总成本3,123,535-3.72%6,702,0486,832,0166,502,5505,501,546
    其中:营业成本2,461,448-3.75%5,296,6225,424,8745,279,7244,406,003
               财务费用27,60715.26%55,83248,38561,34055,294
               资产减值损失(9,392)2,811.27%1,851(1,160)2,596(9,312)
公允价值变动收益(2,409)-10.81%616(10,750)5,8744,210
投资收益22,642463.28%43,0111,8773,9004,630
    其中:对联营企业和合营企业的投资收益24,819423.66%18,90715,60117,18210,645
营业利润477,05220.61%888,104674,258561,482368,002
利润总额474,48519.91%873,578668,550565,418370,887
减:所得税费用108,4445.24%233,694178,709150,40393,663
净利润366,04125.08%639,883489,841415,016277,225
减:非控股权益(2,648)-73.07%(16,422)(16,757)(6,626)4,514
股东净利润368,68921.89%656,306506,598421,642272,711

市场价值指针
每股收益 (元) *0.70020.69%1.2500.9600.8500.580
每股派息 (元) *----0.7620.7620.667--
每股净资产 (元) *4.82414.93%4.8874.3844.1073.120
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容